Bio News
U.S.-based Eli Lilly has signed a joint research agreement with China’s InnoCare covering drugs targeting five targets. Eli Lilly will pay $100 million in upfront and short-term payments. InnoCare will receive development and sales milestone payments, as well as a single-digit royalty based on annual net sales.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
